Table 4 Associations between use of different types of 5α-reductase inhibitors and risk of oesophageal or cardia adenocarcinoma.

From: Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site

Use of 5α-reductase inhibitors

Number of cases

Crude hazard ratio (95% confidence interval)

Adjusted hazard ratio (95% confidence interval)*

Non-users

3328

1.00 (Reference)

1.00 (Reference)

Finasteride only

284

0.93 (0.82–1.05)

0.91 (0.81–1.03)

Dutasteride only

57

0.93 (0.71–1.21)

0.95 (0.73–1.24)

  1. *Adjusted for age, calendar year, gastro-oesophageal reflux disease, obesity or diabetes, Helicobacter pylori treatment, tobacco smoking or smoking-related diagnoses, use of non-steroidal anti-inflammatory drugs or aspirin, and use of statins.
Back to article page